Therapeutic Effect of Tanshinone IIA on Liver Fibrosis and the Possible Mechanism: A Preclinical Meta-Analysis

Table 3

Subgroup and sensitivity analysis of indicators.

Hyp

HA

LN

ALT

SMD (95% CI)

I^2 (%)

SMD (95% CI)

I^2 (%)

SMD (95% CI)

I^2 (%)

SMD (95% CI)

I^2 (%)

Subgroups

Treatment group

−3.08 (−5.14, −1.02)

<0.01

62

−5.86 (−8.12, −3.59)

<0.01

45

−6.92 (−12.76, −1.08)

0.02

89

−7.45 (−11.10, −3.80)

<0.01

93

Prevention group

−6.37 (−12.74, 0.0)

0.05

91

−8.41 (−15.65, −1.18)

0.02

91

−2.21 (−2.87, −1.37)

<0.01

0

−6.49 (−8.17, −4.82)

<0.01

0

Overall

−4.44 (−6.82, −2.06)

<0.01

81

−6.72 (−9.63, −3.81)

<0.01

81

−3.22 (−4.72, −1.73)

<0.01

76

−7.12 (−9.97, −4.27)

<0.01

91

Sensitivity analysis

Treatment group

−3.08 (−5.14, −1.02)

<0.01

62

−5.86 (−8.12, −3.59)

<0.01

45

−9.42 (−13.49, −5.35)

<0.01

34

−7.45 (−11.10, −3.80)

<0.01

93

Prevention group

−3.30 (−5.08, −1.52)

<0.01

—

−11.81 (−18.41, −5.21)

<0.01

64

−2.10 (−2.98, −1.21)

<0.01

0

−6.49 (−8.17, −4.82)

<0.01

0